Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness

Journal of Clinical Psychopharmacology

Volumn 20, Issue 2, 2000, Pages 246-251

  Chou, Wen Hwei ^a   Yan, Feng Xiang ^c   De Leon, Jose ^b,d   Barnhill, John ^b,d   Rogers, Thea ^a,d   Cronin, Maureen ^e   Pho, Mylan ^e   Xiao, Vivian ^e   Ryder, Thomas B ^e   Liu, Wei Wei ^e   Teiling, Clotilde ^e   Wedlund, Peter J ^a,f  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Dali Medical College   (China)

^d EASTERN STATE HOSPITAL   (United States)

^e Thermo Fisher Scientific   (United States)

^f University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DEBRISOQUINE 4 HYDROXYLASE; DESIPRAMINE; DRUG METABOLIZING ENZYME; HALOPERIDOL; IMIPRAMINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PERPHENAZINE; RISPERIDONE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DISEASE SEVERITY; DRUG ELIMINATION; DRUG METABOLISM; ENZYME POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MENTAL PATIENT; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; KENTUCKY; LENGTH OF STAY; NEUROLOGIC EXAMINATION; PILOT PROJECTS; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 0001697297     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200004000-00019     Document Type: Article

References (29)

1. de Leon J, Barnhill J, Rodgers T, Boyle J, Chou WH, Wedlund PJ. A pilot study of cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998;155:1278-80.
2. Edeki T. Clinical importance of genetic polymorphism of drug oxidation. Mt Sinai J Med 1996;63:291-300.
3. Linder MW, Prough RA, Valdes R Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997;43: 254-66.
4. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994;55[suppl]:38-47.
5. Marez D, Legrand M, Sabbagh N, Spire C, Lafitte JJ, Meyer UA, Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202.
6. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variant in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
7. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stüven T, Eichelbaum M. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
8. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36:537-47.
9. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994;46[suppl 1]:417-24.
10. Müller N, Brockmöller J, Roots I. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450II D6 29/29-kilobase wild-type allele-a slowly reversible interaction with fluoxetine. Ther Drug Monit 1991;13:533-6.
11. Bluhm RE, Wilkinson GR, Shelton R, Branch RA. Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin Pharmacol Ther 1993;53:89-95.
12. Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995;15:211-6.
13. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997;170:23-6.
14. Spigset O, Hedenmalm K, Dahl ML, Wiholm BE, Dahlqvist R. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997;96:379-84.
15. Chen S, Chou WH, Blouin RA, Humphries LL, Meek QC, Neil JR, Martin WL, Wedlund PJ. The cytochrome P450-2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcome in psychiatry. Clin Pharmacol Ther 1996;60:522-34.
16. Spina E, Gitto C, Avenso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997;51:395-8.
17. Agundez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57: 265-9.
18. Clark DW, Morgan AKW, Waal-Manning H. Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol 1984;18:965-7.
19. Wynne H, Lancaster R, Oates NS, Crothers MJ, Idle JR, Smith RL. Debrisoquine oxidation, phenotyping, and adverse drug reactions: utility of phenotyping in general hospital admissions. Proc Br Pharmacol Soc 1985;20:254P-255P.
20. Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, Guentert TW, Henauer S, Jackson P, Laux G, Mikkelsen H, Peck C, Pollock BG, Priest R, Sjoqvist F, Delini-Stula A. Antidepressants and drug-metabolizing enzyme-expert group report. Acta Psychiatr Scand 1996;93:71-9.
21. McLellan RA, Oscarson M, Seidegard J, Evans DAP, Ingleman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;7:187-91.
22. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Utrarapid metabolizers of debrisoquine: characterization and CYP-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996;392:30-4.
23. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6(D) gene duplication allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
24. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996;42:713-9.
25. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-speciflc PCR amplification. Lancet 1990;336: 529-32.
26. Lovlie R, Daly AK, Idle JR, Steen VM. Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes. Pharmacogenetics 1997;7:149-52
27. Cronin MT, Lee D, Pho M, Hahnenberger KM, Lin C, Kanemoto R, Chou WH, Wedlund PJ. Comparison of CYP2D6 genotyping by oligonucleotide array hybridization and a PCR based method [abstract]. ISSX Proc 1996;10:242.
28. Cronin MT, Fusini RV, Kim SM, Masino RS, Wespi RM, Miyada CB. Cystic fibrosis mutation detection by hybridization to light generated DNA probe arrays. Hum Mutat 1996;7:244-55.
29. Sachse C, Brockmöller J, Hildebrand M, Müller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998;8:181-5.